PMID- 32730518
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 0717-6228 (Electronic)
IS  - 0370-4106 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jun
TI  - [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with 
      neuroblastoma].
PG  - 379-384
LID - S0370-41062020005000701 [pii]
LID - 10.32641/rchped.v91i3.1237 [doi]
AB  - INTRODUCTION: The treatment of advanced neuroblastoma includes chemotherapy, 
      surgery, and radiotherapy with 131-I-Metaiodobenzylguanidine (131-I-MIBG). 
      Despite strategies to protect thyroid function, its dysfunction is reported 
      between 12 and 85%. OBJECTIVE: To identify the frequency of thyroid dys function 
      in cases of neuroblastoma treated with 131-I-MIBG. PATIENTS AND METHOD: 
      Cross-sectional study. We included all the cases with neuroblastoma treated with 
      131-I-MIBG between 2002 and 2015, with complete somatometry, and complete thyroid 
      profile (TSH, free and total T3 and T4, and anti-thyroglobulin and antiperoxidase 
      antibodies). RESULTS: 27 patients were identified out of which eleven died (40%). 
      Out of the 16 surviving cases, 9 (56%) presented thyroid dysfunction: 2 (13%) 
      cases with subclinical hypothyroidism and 7 (44%) cases with clinical 
      hypothyroidism (3 cases due to psychomotor developmental delay and 4 due to 
      growth deceleration). The patients presented cli nical manifestations at 16.1 
      months (1.2-66.3 months) after receiving the radiopharmaceutical at a cumulative 
      dose of 142 mCi (96-391.5 mCi). No differences were found in the age at 
      diagnosis, age at the start of treatment with 131-I-MIBG, the cumulative dose of 
      131-I-MIBG, and the time elapsed between the dose and the thyroid profile among 
      the cases with or without thyroid dysfunction. Con clusions: 56% of patients with 
      neuroblastoma had thyroid dysfunction. Most of the cases with hy pothyroidism 
      were referred when thyroid dysfunction was clinically evident. A thyroid profile 
      should be performed every 6 months, along with an annual endocrinological 
      evaluation during the next 5 years in these patients.
FAU - Garrido Magana, Eulalia
AU  - Garrido Magana E
AD  - UMAE Hospital de Pediatria, centro Medico Nacional Siglo XXI, Instituto Mexicano 
      del Seguro Social, ciudad de Mexico, Mexico.
FAU - Silva Estrada, Jorge Alberto
AU  - Silva Estrada JA
AD  - Hospital Central Sur de Alta Especialidad de Petroleos Mexicanos, Ciudad de 
      Mexico, Mexico.
FAU - Nishimura Meguro, Elisa
AU  - Nishimura Meguro E
AD  - UMAE Hospital de Pediatria, centro Medico Nacional Siglo XXI, Instituto Mexicano 
      del Seguro Social, ciudad de Mexico, Mexico.
FAU - Rivera Hernandez, Aleida de Jesus
AU  - Rivera Hernandez AJ
AD  - UMAE Hospital de Pediatria, centro Medico Nacional Siglo XXI, Instituto Mexicano 
      del Seguro Social, ciudad de Mexico, Mexico.
FAU - Zurita Cruz, Jessie Nallely
AU  - Zurita Cruz JN
AD  - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico.
LA  - spa
PT  - Journal Article
TT  - Disfuncion tiroidea por I131-Metayodo Benzilguanidina en pacientes con 
      neuroblastoma.
PL  - Chile
TA  - Rev Chil Pediatr
JT  - Revista chilena de pediatria
JID - 0404261
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Iodine-131)
RN  - 0 (Radiopharmaceuticals)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
MH  - 3-Iodobenzylguanidine/*adverse effects/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Hypothyroidism/diagnosis/epidemiology/*etiology
MH  - Infant
MH  - Iodine Radioisotopes/*adverse effects/therapeutic use
MH  - Male
MH  - Neuroblastoma/*radiotherapy
MH  - Radiopharmaceuticals/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thyroid Diseases
EDAT- 2020/07/31 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/07/31 06:00
PHST- 2019/05/13 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
AID - S0370-41062020005000701 [pii]
AID - 10.32641/rchped.v91i3.1237 [doi]
PST - ppublish
SO  - Rev Chil Pediatr. 2020 Jun;91(3):379-384. doi: 10.32641/rchped.v91i3.1237.